Catalent, Inc. or ADMA Biologics, Inc.: Who Manages SG&A Costs Better?

Catalent, Inc. vs. ADMA Biologics, Inc.: A Decade of SG&A Management

In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Catalent, Inc. and ADMA Biologics, Inc. have demonstrated contrasting approaches to SG&A cost management. From 2014 to 2023, Catalent's SG&A expenses have consistently been higher, peaking at approximately $935 million in 2024, reflecting its expansive operations and market reach. In contrast, ADMA Biologics, Inc. has shown a steady increase in SG&A expenses, reaching around $59 million in 2023, indicating a more conservative growth strategy.

Catalent's expenses have grown by about 180% over the decade, while ADMA's have surged by over 1,100%, albeit from a much smaller base. This data highlights the different scales and strategies of these companies, offering insights into their operational efficiencies and market positioning.